Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.
Völkel S, Tarawneh TS, Sacher L, Bhagwat AM, Karim I, Mack HID, Wiesmann T, Beutel B, Hoyer J, Keller C, Renz H, Burchert A, Neubauer A, Graumann J, Skevaki C, Mack EKM. Völkel S, et al. Among authors: keller c. Front Med (Lausanne). 2023 May 24;10:1176427. doi: 10.3389/fmed.2023.1176427. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37293294 Free PMC article.
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A, Johow J, Mack E, Burchert A, Meyn D, Kadlubiec A, Torje I, Wulf H, Vogelmeier CF, Hoyer J, Skevaki C, Muellenbach RM, Keller C, Schade-Brittinger C, Rolfes C, Wiesmann T. Neubauer A, et al. Among authors: keller c. Leukemia. 2021 Oct;35(10):2917-2923. doi: 10.1038/s41375-021-01374-3. Epub 2021 Aug 12. Leukemia. 2021. PMID: 34385593 Free PMC article. Clinical Trial.
Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A, Johow J, Mack E, Burchert A, Meyn D, Kadlubiec A, Torje I, Wulf H, Vogelmeier CF, Hoyer J, Skevaki C, Muellenbach RM, Keller C, Schade-Brittinger C, Rolfes C, Wiesmann T. Neubauer A, et al. Among authors: keller c. Leukemia. 2021 Oct;35(10):3038. doi: 10.1038/s41375-021-01412-0. Leukemia. 2021. PMID: 34518646 Free PMC article. No abstract available.
Single-cell RNA sequencing uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19.
Aznaourova M, Schmerer N, Janga H, Zhang Z, Pauck K, Bushe J, Volkers SM, Wendisch D, Georg P, Ntini E, Aillaud M, Gündisch M, Mack E, Skevaki C, Keller C, Bauer C, Bertrams W, Marsico A, Nist A, Stiewe T, Gruber AD, Ruppert C, Li Y, Garn H, Sander LE, Schmeck B, Schulte LN. Aznaourova M, et al. Among authors: keller c. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2120680119. doi: 10.1073/pnas.2120680119. Epub 2022 Aug 23. Proc Natl Acad Sci U S A. 2022. PMID: 35998224 Free PMC article.
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies.
Krähling V, Halwe S, Rohde C, Becker D, Berghöfer S, Dahlke C, Eickmann M, Ercanoglu MS, Gieselmann L, Herwig A, Kupke A, Müller H, Neubauer-Rädel P, Klein F, Keller C, Becker S. Krähling V, et al. Among authors: keller c. J Immunol Methods. 2021 Mar;490:112958. doi: 10.1016/j.jim.2021.112958. Epub 2021 Jan 4. J Immunol Methods. 2021. PMID: 33412174 Free PMC article.
TMPRSS2, a novel host-directed drug target against SARS-CoV-2.
Keller C, Böttcher-Friebertshäuser E, Lohoff M. Keller C, et al. Signal Transduct Target Ther. 2022 Jul 23;7(1):251. doi: 10.1038/s41392-022-01084-x. Signal Transduct Target Ther. 2022. PMID: 35871159 Free PMC article. No abstract available.
1,823 results